Age-related visual impairments and retinal ganglion cells axonal degeneration in a mouse model harboring OPTN (E50K) mutation.
Mingying HouZhengbo ShaoShiqi ZhangXinna LiuPan FanMenglu JiangYutong ZhaoRong XiaoHuiping YuanPublished in: Cell death & disease (2022)
Retinal ganglion cells (RGCs) axons are the signal carriers of visual information between retina and brain. Therefore, they play one of the important roles affected in many optic neurodegenerative diseases like glaucoma. Among the genetic risks associated with glaucoma, the E50K mutation in the Optineurin (OPTN) gene are known to result in glaucoma in the absence of increased intraocular pressure (IOP), whereas the relevant pathological mechanism and neurological issues remain to be further investigated. In this study, the OPTN (E50K) mutant mouse model was established through CRISPR/Cas9-mediated genome editing, and aging-related RGCs loss and the visual dysfunction were identified. In E50K mice 16 months old, the axonal transport decreased comparing to wild-type (WT) mice at the same age. Furthermore, results of electron microscopy demonstrated significant morphological anomaly of mitochondria in RGCs axons of young E50K mice 3 months old, and these changes were aggravated with age. These indicated that the damaged mitochondria-associated dysfunction of RGCs axon should play an etiological role in glaucoma as an age-related outcome of OPTN (E50K) mutation. The findings of this study have potential implications for the targeted prevention and treatment of NTG.
Keyphrases
- optic nerve
- crispr cas
- wild type
- genome editing
- mouse model
- induced apoptosis
- optical coherence tomography
- spinal cord injury
- oxidative stress
- high fat diet induced
- cell cycle arrest
- genome wide
- copy number
- electron microscopy
- healthcare
- human health
- multiple sclerosis
- health information
- adipose tissue
- signaling pathway
- diabetic retinopathy
- cancer therapy
- climate change
- gene expression
- drug delivery
- high resolution
- functional connectivity
- combination therapy
- smoking cessation
- atomic force microscopy
- replacement therapy